{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T18:05:39Z","timestamp":1784311539050,"version":"3.55.0"},"reference-count":62,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dyslipidemia is one of the main risk factors for cardiovascular diseases worldwide. The current study aimed to determine the prevalence and correlates of dyslipidemia in Iran, in addition to factors associated with receiving treatment and attaining treatment goals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The current study used the data of a very large cross-sectional survey, Prospective Epidemiological Research Studies in IrAN (PERSIAN), including 163,770 Iranians aged 35\u201370 years from 18 distinct areas across Iran, between 2014 and 2020. Participants\u2019 characteristics were recorded using validated questionnaires including biological samples, physical measurements, and self-reported information. Dyslipidemia was defined according to the Third Report of the Adult Treatment Panel. Triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL) and low-density lipoprotein (LDL) were measured as components of dyslipidemia. We calculated participants\u2019 10-years cardiovascular risk using the World Health Organization risk charts to assess the eligibility for treatment and achievement of control. Multivariable logistic regression analyses were conducted to investigate the correlates of dyslipidemia, receiving treatment, and control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean age of participants was 49.4 (\u00b19.1) years, among whom 55% were women and 70% were urban residents. The weighted prevalence of dyslipidemia was 73.2% (95% CI: 71.5\u201375.0%). High TG (40.4%, 36.9%\u221244.4%) and high TC (36.2%, 32.9%\u221239.4%) comprised the most prevalent components of dyslipidemia, followed by low HDL-C (32.1%, 25.8%\u221238.4%), high non-HDL-C (26.6%, 24.0%\u221229.1%), and high LDL-C (23.4%, 21.1%\u221225.7%). In multivariable logistic regression analysis, younger age, tobacco consumption, low physical activity, high BMI, diabetes, and hypertension were associated with low HDL-C and high TG. Older age, alcohol consumption, low physical activity, and high BMI were associated with high TC and high LDL-C. Women had higher likelihood of having abnormal levels for all components of dyslipidemia, except for high TG. Older age, high wealth score, high BMI, and low physical activity were associated with higher utilization of statin treatment. Good lipid control in those who were treated with statin was higher in males and diabetics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The prevalence of dyslipidemia in Iranian population is extremely high, and certain groups are at higher risk of poor lipid control. Findings of this study highlight the necessity of developing a national guideline for management of dyslipidemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0352516","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:51:07Z","timestamp":1784310667000},"page":"e0352516","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epidemiology and determinants of dyslipidemia in Iranian population: Results from the PERSIAN cohort"],"prefix":"10.1371","volume":"21","author":[{"given":"Nazgol","family":"Motamed-Gorji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadaf G.","family":"Sepanlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Moallemian Isfahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meysam","family":"Alipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7345-0796","authenticated-orcid":true,"given":"Azizallah","family":"Dehghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedram","family":"Ebrahimnejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohhamad Reza","family":"Fattahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoumeh","family":"Goddusi Johari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Jamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Ali","family":"Kaykhaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyyedadel","family":"Khoshbou_Garebagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariborz","family":"Mansour-Ghanaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3404-8868","authenticated-orcid":true,"given":"Somaieh","family":"Matin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Mirzaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6347-0163","authenticated-orcid":true,"given":"Azim","family":"Nejatizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Ostadrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayoob","family":"Rastegar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moslem","family":"Sedaghattalab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebrahim","family":"Shakiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sareh","family":"Eghtesad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Poustchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9820-6335","authenticated-orcid":true,"given":"Reza","family":"Malekzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"25","key":"pone.0352516.ref001","first-page":"2982","article-title":"Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study","volume":"76","author":"GA Roth","year":"2020","journal-title":"J Am College Cardiol"},{"issue":"25","key":"pone.0352516.ref002","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","article-title":"Global Burden of Cardiovascular Diseases and Risks, 1990-2022","volume":"82","author":"GA Mensah","year":"2023","journal-title":"J Am College Cardiol"},{"issue":"3","key":"pone.0352516.ref003","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1161\/ATVBAHA.115.305380","article-title":"Atherosclerosis","volume":"35","author":"H Lu","year":"2015","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"7","key":"pone.0352516.ref004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254631","article-title":"The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies","volume":"16","author":"P Ferrara","year":"2021","journal-title":"PLoS One"},{"issue":"7","key":"pone.0352516.ref005","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.3788","article-title":"Association Between Obesity and Cardiovascular Outcomes: A Systematic Review and Meta-analysis of Mendelian Randomization Studies","volume":"1","author":"H Riaz","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"1","key":"pone.0352516.ref006","doi-asserted-by":"crossref","first-page":"15499","DOI":"10.1038\/s41598-023-42341-5","article-title":"Prevalence of plasma lipid abnormalities and associated risk factors among Iranian adults based on the findings from STEPs survey 2021","volume":"13","author":"J Khanali","year":"2023","journal-title":"Sci Rep"},{"issue":"2","key":"pone.0352516.ref007","doi-asserted-by":"crossref","first-page":"51","DOI":"10.34172\/aim.2024.10","article-title":"Epidemiology and prevalence of dyslipidemia among adult population of Tehran: the Tehran cohort study","volume":"27","author":"A Shafiee","year":"2024","journal-title":"Archives of Iranian Medicine"},{"issue":"6","key":"pone.0352516.ref008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2018.08.001","article-title":"The prevalence, awareness, and treatment of lipid abnormalities in Iranian adults: Surveillance of risk factors of noncommunicable diseases in Iran 2016","volume":"12","author":"Z Aryan","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"1","key":"pone.0352516.ref009","doi-asserted-by":"crossref","first-page":"50","DOI":"10.5534\/wjmh.17014","article-title":"Prevalence of Metabolic Syndrome and Associations with Lipid Profiles in Iranian Men: A Population-Based Screening Program","volume":"36","author":"A Mohammadbeigi","year":"2018","journal-title":"World J Mens Health"},{"issue":"4","key":"pone.0352516.ref010","first-page":"373","article-title":"Prevalence of dyslipidemia in iran: a systematic review and meta-analysis study","volume":"5","author":"O Tabatabaei-Malazy","year":"2014","journal-title":"Int J Prev Med"},{"issue":"5","key":"pone.0352516.ref011","first-page":"449","article-title":"Prevalence of Hypercholesterolemia, High LDL, and Low HDL in Iran: A Systematic Review and Meta-Analysis","volume":"43","author":"PhD Akbartabar Toori M","year":"2018","journal-title":"Iran J Med Sci"},{"issue":"1","key":"pone.0352516.ref012","doi-asserted-by":"crossref","first-page":"9125","DOI":"10.1038\/s41598-021-88680-z","article-title":"Dyslipidemia and its associated factors in southern Iranian women, Bandare-Kong Cohort study, a cross-sectional survey","volume":"11","author":"M Nikparvar","year":"2021","journal-title":"Sci Rep"},{"issue":"11","key":"pone.0352516.ref013","first-page":"691","article-title":"The PERSIAN Cohort: Providing the Evidence Needed for Healthcare Reform","volume":"20","author":"S Eghtesad","year":"2017","journal-title":"Arch Iran Med"},{"issue":"4","key":"pone.0352516.ref014","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/aje\/kwx314","article-title":"Prospective Epidemiological Research Studies in Iran (the PERSIAN Cohort Study): Rationale, Objectives, and Design","volume":"187","author":"H Poustchi","year":"2018","journal-title":"Am J Epidemiol"},{"issue":"6","key":"pone.0352516.ref015","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"WT Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"pone.0352516.ref016","year":"2007"},{"issue":"11","key":"pone.0352516.ref017","article-title":"2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"152","author":"Members* Writing Committee","year":"2025","journal-title":"Circulation"},{"key":"pone.0352516.ref018","article-title":"Targets for treatment and optimal strategies for non-pharmacological and pharmacological management of hypertension","author":"BH van den Born","year":"2025","journal-title":"European Journal of Preventive Cardiology"},{"key":"pone.0352516.ref019","author":"NHLBI Obesity Education Initiative","year":"1998"},{"key":"pone.0352516.ref020","article-title":"2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020","volume":"43","author":"American Diabetes Association","year":"2020","journal-title":"Diabetes Care"},{"issue":"19","key":"pone.0352516.ref021","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults","volume":"285","author":"III Adult Treatment Panel","year":"2001","journal-title":"JAMA"},{"key":"pone.0352516.ref022","author":"World Health Organization","year":"2007"},{"issue":"10","key":"pone.0352516.ref023","article-title":"World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions","volume":"7","author":"WHO CVD Risk Chart Working Group","year":"2019","journal-title":"Lancet Glob Health"},{"key":"pone.0352516.ref024","unstructured":"World Health Organization. WHO package of essential noncommunicable (PEN) disease interventions for primary health care. 2020."},{"issue":"8","key":"pone.0352516.ref025","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22579","article-title":"Prevalence of combined and noncombined dyslipidemia in an Iranian population","volume":"32","author":"S Darroudi","year":"2018","journal-title":"J Clin Lab Anal"},{"issue":"5","key":"pone.0352516.ref026","first-page":"925","article-title":"Prevalence of Dyslipidemia in Urban and Rural Areas of the Northwest of Iran: The Sociodemographic, Dietary and Psychological Determinants","volume":"48","author":"JS Tabrizi","year":"2019","journal-title":"Iran J Public Health"},{"issue":"4","key":"pone.0352516.ref027","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jacl.2012.05.002","article-title":"Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006","volume":"6","author":"PP T\u00f3th","year":"2012","journal-title":"J Clin Lipidol"},{"issue":"1","key":"pone.0352516.ref028","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12944-017-0453-2","article-title":"The prevalence, awareness, treatment, and control of dyslipidemia in northeast China: a population-based cross-sectional survey","volume":"16","author":"F-L Zhang","year":"2017","journal-title":"Lipids Health Dis"},{"issue":"11","key":"pone.0352516.ref029","doi-asserted-by":"crossref","first-page":"102870","DOI":"10.1016\/j.dsx.2023.102870","article-title":"Prevalence of dyslipidemias in the Middle East region: A systematic review & meta-analysis study","volume":"17","author":"S Kargar","year":"2023","journal-title":"Diabetes Metab Syndr"},{"issue":"4","key":"pone.0352516.ref030","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3132\/dvdr.2008.046","article-title":"The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient","volume":"5","author":"J-C Fruchart","year":"2008","journal-title":"Diab Vasc Dis Res"},{"key":"pone.0352516.ref031","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12933-014-0159-y","article-title":"Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor","volume":"13","author":"A Tenenbaum","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"pone.0352516.ref032","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.maturitas.2015.02.262","article-title":"Effects of menopause, gender and age on lipids and high-density lipoprotein cholesterol subfractions","volume":"81","author":"P Anagnostis","year":"2015","journal-title":"Maturitas"},{"issue":"6","key":"pone.0352516.ref033","first-page":"370","article-title":"Determinants of prevalence, awareness, treatment and control of high LDL-C in Turkey","volume":"16","author":"K S\u00f6zmen","year":"2016","journal-title":"Anatol J Cardiol"},{"issue":"51","key":"pone.0352516.ref034","article-title":"Evaluating the prevalence, awareness, and control of hypertension, diabetes, and dyslipidemia in Korea using the NHIS-NSC database: A cross-sectional analysis","volume":"97","author":"S Boo","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"pone.0352516.ref035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12944-020-1189-y","article-title":"Associations between age and dyslipidemia are differed by education level: The Cardiovascular and Metabolic Diseases Etiology Research Center (CMERC) cohort","volume":"19","author":"SMJ Cho","year":"2020","journal-title":"Lipids Health Dis"},{"key":"pone.0352516.ref036","doi-asserted-by":"crossref","first-page":"100666","DOI":"10.1016\/j.ajpc.2024.100666","article-title":"Unique features of dyslipidemia in women across a lifetime and a tailored approach to management","volume":"18","author":"N Patel","year":"2024","journal-title":"Am J Prev Cardiol"},{"issue":"8","key":"pone.0352516.ref037","first-page":"1596","article-title":"A comparative study of lipid profile and oestradiol in pre- and post-menopausal women","volume":"7","author":"S Reddy Kilim","year":"2013","journal-title":"J Clin Diagn Res"},{"issue":"10","key":"pone.0352516.ref038","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1056\/NEJM198909073211004","article-title":"Menopause and risk factors for coronary heart disease","volume":"321","author":"KA Matthews","year":"1989","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0352516.ref039","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12944-018-0768-7","article-title":"Dyslipidemia prevalence, awareness, treatment, control, and risk factors in Chinese rural population: the Henan rural cohort study","volume":"17","author":"X Liu","year":"2018","journal-title":"Lipids Health Dis"},{"issue":"1","key":"pone.0352516.ref040","article-title":"Prevalence and related factors of dyslipidemia among urban adults aged 35 to 79 years in Southwestern China","volume":"11","author":"C Huang","year":"2021","journal-title":"Scientific reports"},{"issue":"1","key":"pone.0352516.ref041","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3390\/nu14010050","article-title":"Association between Health-Related Physical Fitness and Risk of Dyslipidemia in University Staff: A Cross-Sectional Study and a ROC Curve Analysis","volume":"14","author":"Y Zhou","year":"2021","journal-title":"Nutrients"},{"issue":"1","key":"pone.0352516.ref042","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ihj.2021.12.005","article-title":"Association of the lipoprotein lipase and Apolipoprotein C-II gene polymorphisms with risk of dyslipidemia in smokers and non-smokers male","volume":"74","author":"RI Al-Samawi","year":"2022","journal-title":"Indian Heart J"},{"issue":"6","key":"pone.0352516.ref043","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jacl.2009.10.008","article-title":"Smoking intensity and lipoprotein abnormalities in active smokers","volume":"3","author":"LK Gossett","year":"2009","journal-title":"J Clin Lipidol"},{"issue":"1","key":"pone.0352516.ref044","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.atherosclerosis.2005.05.040","article-title":"Effect of smoking habit on age-related changes in serum lipids: a cross-sectional and longitudinal analysis in a large Japanese cohort","volume":"185","author":"M Kuzuya","year":"2006","journal-title":"Atherosclerosis"},{"issue":"1","key":"pone.0352516.ref045","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1253\/circj.70.8","article-title":"Low-grade inflammation, thrombogenicity, and atherogenic lipid profile in cigarette smokers","volume":"70","author":"H Yasue","year":"2006","journal-title":"Circ J"},{"issue":"9","key":"pone.0352516.ref046","article-title":"Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China","volume":"4","author":"Y Lu","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"5","key":"pone.0352516.ref047","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0022-2275(20)41437-3","article-title":"Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol","volume":"33","author":"M Hannuksela","year":"1992","journal-title":"J Lipid Res"},{"issue":"9493","key":"pone.0352516.ref048","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"C Baigent","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"pone.0352516.ref049","first-page":"109","article-title":"Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol--United States, 1999-2002 and 2005-200","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Morbidity and mortality weekly report"},{"issue":"3","key":"pone.0352516.ref050","article-title":"US Trends in Cholesterol Screening, Lipid Levels, and Lipid-Lowering Medication Use in US Adults, 1999 to 2018","volume":"12","author":"Y Gao","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"pone.0352516.ref051","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/ije\/dyi056","article-title":"Prevalence, awareness and treatment of hypercholesterolaemia in 32 populations: results from the WHO MONICA Project","volume":"34","author":"H Tolonen","year":"2005","journal-title":"Int J Epidemiol"},{"issue":"8","key":"pone.0352516.ref052","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.005562","article-title":"Sex Differences in the Use of Statins in Community Practice","volume":"12","author":"MG Nanna","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"11","key":"pone.0352516.ref053","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028892","article-title":"Evolving Management of Low-Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum","volume":"12","author":"MJ Wilkinson","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"pone.0352516.ref054","doi-asserted-by":"crossref","first-page":"100177","DOI":"10.1016\/j.ajpc.2021.100177","article-title":"Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC\/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States","volume":"6","author":"SJ Baum","year":"2021","journal-title":"Am J Prev Cardiol"},{"issue":"9","key":"pone.0352516.ref055","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamacardio.2021.1810","article-title":"Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US","volume":"6","author":"CP Cannon","year":"2021","journal-title":"JAMA Cardiol"},{"key":"pone.0352516.ref056","doi-asserted-by":"crossref","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"KK Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"6","key":"pone.0352516.ref057","doi-asserted-by":"crossref","first-page":"273","DOI":"10.14744\/AnatolJCardiol.2024.4218","article-title":"Adherence to Current Dyslipidemia Guideline in Patients Utilizing Statins According to Risk Groups and Gender Differences: The AIZANOI Study","volume":"28","author":"T \u015een","year":"2024","journal-title":"Anatol J Cardiol"},{"key":"pone.0352516.ref058","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.atherosclerosis.2021.02.024","article-title":"Inferior control of low-density lipoprotein cholesterol in women is the primary sex difference in modifiable cardiovascular risk: A large-scale, cross-sectional study in primary care","volume":"324","author":"Y Rachamin","year":"2021","journal-title":"Atherosclerosis"},{"issue":"4","key":"pone.0352516.ref059","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.amjcard.2015.05.011","article-title":"Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry)","volume":"116","author":"SA Spinler","year":"2015","journal-title":"Am J Cardiol"},{"key":"pone.0352516.ref060","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.atherosclerosis.2019.03.017","article-title":"Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy","volume":"285","author":"V Presta","year":"2019","journal-title":"Atherosclerosis"},{"issue":"10","key":"pone.0352516.ref061","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.numecd.2020.04.030","article-title":"Prevalence of poor lipid control in patients with premature coronary artery disease","volume":"30","author":"M-S Froylan D","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"pone.0352516.ref062","article-title":"10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0352516","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:51:28Z","timestamp":1784310688000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0352516"}},"subtitle":[],"editor":[{"given":"Festo Casmir","family":"Shayo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":62,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0352516","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}